Skip to main content

Advertisement

Table 2 Baseline characteristics of study patients

From: A randomized, placebo-controlled study of the cardiovascular safety of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus

  Omarigliptin N = 2100 Placebo N = 2102
Age, years 63.7 ± 8.5 63.6 ± 8.5
Male, n (%) 1461 (69.6) 1487 (70.7)
Race, n (%)
 White 1707 (81.3) 1709 (81.3)
 Asian 234 (11.1) 221 (10.5)
 Black 73 (3.5) 87 (4.1)
 Multi-racial 67 (3.2) 67 (3.2)
 American Indian/Alaska Native 13 (0.6) 12 (0.6)
 Native Hawaiian or Other Pacific Islander 6 (0.3) 6 (0.3)
Ethnicity, n (%)
 Not Hispanic or Latino 1813 (86.3) 1814 (86.3)
 Hispanic or Latino 267 (12.7) 266 (12.7)
 Not reported 13 (0.6) 10 (0.5)
 Unknown 7 (0.3) 12 (0.6)
Body weight, kg 89.0 ± 18.5 89.6 ± 18.8
BMI, kg/m2 31.2 ± 5.5 31.4 ± 5.6
Geographic region
 North America 431 (20.5) 450 (21.4)
 Europe 1166 (55.5) 1169 (55.6)
 Latin America 140 (6.7) 144 (6.9)
 Asia 201 (9.6) 180 (8.6)
 Othera 162 (7.7) 159 (7.6)
HbA1c, % 8.0 ± 0.9 8.0 ± 0.9
Duration of diabetes, years 12.0 ± 7.6 12.1 ± 8.0
eGFR (mL/min/1.73 m2) 85.7 ± 24.5 86.6 ± 25.5
History of congestive heart failure 341 (16.2) 300 (14.3)
History of hypertension 1998 (95.1) 2010 (95.6)
Cigarette smoking status
 Current 301 (14.3) 305 (14.5)
 Former 825 (39.3) 815 (38.8)
 Never 974 (46.4) 981 (46.7)
 Unknown 0 (0.0) 1 (0.0)
Prior AHA therapy
 Insulin 769 (36.6) 699 (33.3)
 Metformin 1646 (78.4) 1606 (76.4)
 Sulfonylurea 817 (38.9) 826 (39.3)
 SGLT2 inhibitor 4 (0.2) 4 (0.2)
 Thiazolidinedione 24 (1.1) 21 (1.0)
 Other 55 (2.6) 55 (2.6)
 None 71 (3.4) 84 (4.0)
  1. Values are mean ± SD or n (%)
  2. BMI body mass index, eGFR estimated glomerular filtration rate, AHA anti-hyperglycemic agent, SGLT2 sodium–glucose linked transporter 2
  3. aFor geographic region, other includes Australia, Israel, Lebanon, New Zealand and South Africa